Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Catalyst Pharmaceuticals, Inc.'s quarterly P/E stands at 14.6x, up 23.0% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 8.7% YoY to 8.0x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 13.74 | 14.59 | 11.73 | 13.23 | 13.47 | 11.86 | 14.20 | 11.73 | 20.97 | 13.56 | — | 10.18 | 15.94 |
| — | +23.0% | -17.4% | +12.8% | -35.8% | -12.5% | — | +15.3% | +31.6% | -35.9% | — | +16.2% | -7.7% | |
| P/S Ratio | 4.80 | 4.87 | 4.22 | 4.72 | 5.44 | 4.65 | 4.84 | 3.93 | 4.99 | 4.32 | 3.03 | 3.84 | 5.53 |
| — | +4.7% | -12.9% | +20.0% | +9.0% | +7.5% | +59.7% | +2.6% | -9.8% | -50.2% | -51.7% | +6.4% | +5.5% | |
| P/B Ratio | 3.08 | 3.11 | 2.72 | 3.23 | 3.88 | 3.62 | 3.77 | 3.17 | 3.50 | 4.93 | 3.57 | 4.07 | 5.66 |
| — | -14.1% | -27.9% | +1.9% | +10.6% | -26.5% | +5.5% | -22.1% | -38.1% | -29.9% | -32.8% | +28.1% | +38.0% | |
| P/FCF | 13.55 | 16.55 | 19.30 | 9.71 | 12.82 | 9.31 | 8.58 | 7.53 | 15.50 | 8.96 | 6.91 | 12.42 | — |
| — | +77.8% | +124.8% | +29.0% | -17.3% | +3.8% | +24.2% | -39.4% | — | -31.9% | -20.5% | +69.7% | — | |
| EV / EBITDA | 7.18 | 7.97 | 6.00 | 6.99 | 8.59 | 7.33 | 10.09 | 6.12 | 11.35 | 8.74 | — | 6.12 | 10.34 |
| — | +8.7% | -40.5% | +14.2% | -24.4% | -16.1% | — | +0.0% | +9.8% | -39.4% | — | +25.2% | -1.4% | |
| EV / EBIT | 8.23 | 10.46 | 6.39 | 7.64 | 9.87 | 8.44 | 10.09 | 7.18 | 15.30 | 10.66 | — | 7.24 | 12.25 |
| — | +24.0% | -36.6% | +6.4% | -35.5% | -20.9% | — | -0.8% | +24.9% | -22.5% | — | +48.0% | +16.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Catalyst Pharmaceuticals, Inc.'s operating margin was 40.5% in Q4 2025, down 4.1 pp QoQ and down 3.8 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 43.8% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 7.1% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.2% | 90.8% | 82.9% | 79.6% | 87.3% | 84.7% | 85.0% | 87.4% | 87.3% | 85.7% | 86.2% | 87.9% | 88.3% |
| — | +7.1% | -2.4% | -9.0% | +0.1% | -1.1% | -1.4% | -0.5% | -1.2% | +5.1% | +3.7% | +2.7% | +2.3% | |
| Operating Margin | 43.8% | 40.5% | 44.7% | 45.2% | 44.8% | 44.3% | 39.6% | 44.2% | 27.5% | 37.7% | -36.2% | 46.9% | 41.7% |
| — | -8.5% | +12.9% | +2.3% | +62.7% | +17.5% | +209.2% | -5.7% | -34.0% | -25.6% | -182.6% | -12.8% | +3.5% | |
| Net Margin | 36.4% | 34.5% | 35.6% | 35.6% | 40.1% | 39.4% | 34.1% | 33.2% | 23.6% | 31.5% | -30.0% | 37.9% | 34.6% |
| — | -12.5% | +4.3% | +6.9% | +69.8% | +25.2% | +213.8% | -12.3% | -31.8% | -24.8% | -175.4% | -6.8% | +12.7% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.5% | 5.6% | 5.9% | 6.3% | 7.5% | 8.1% | 6.9% | 7.0% | 4.9% | 9.5% | -8.5% | 10.7% | 9.3% |
| — | -30.2% | -14.0% | -9.4% | +52.1% | -14.9% | +181.3% | -34.5% | -47.4% | +6.0% | -195.5% | +13.7% | +50.4% | |
| ROA | 21.9% | 4.9% | 5.2% | 5.5% | 6.4% | 6.9% | 5.9% | 6.0% | 4.2% | 7.9% | -7.2% | 8.9% | 7.6% |
| — | -29.0% | -12.1% | -8.1% | +54.7% | -12.7% | +182.7% | -32.0% | -44.8% | +9.8% | -194.7% | +5.5% | +38.3% | |
| ROIC | 83.9% | 19.3% | 22.6% | 23.5% | 22.1% | 21.7% | 16.7% | 16.6% | 8.0% | 12.9% | -12.9% | 18.0% | 27.4% |
| — | -10.9% | +35.7% | +41.8% | +176.1% | +68.0% | +228.9% | -7.8% | -70.8% | -93.3% | -117.9% | -66.3% | -10.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Catalyst Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.0x, down from 0.0x last quarter — comfortably within a safe range. The current ratio has improved 17.6% YoY to 6.08x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -43.8% | -36.8% | -37.0% | -37.0% | -52.2% | -52.5% | -44.2% | -45.9% | -29.3% | -29.0% | -40.9% | -39.0% | |
| Debt / EBITDA | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.09 | 0.07 | — | 0.07 | 0.09 |
| — | -24.9% | -40.8% | -25.5% | -55.3% | -37.0% | — | -21.4% | +5.0% | -43.4% | — | -52.4% | -61.9% | |
| Current Ratio | 6.08 | 6.08 | 6.62 | 6.71 | 6.14 | 5.17 | 5.11 | 5.14 | 5.09 | 2.88 | 3.32 | 4.59 | 3.51 |
| — | +17.6% | +29.5% | +30.6% | +20.8% | +79.2% | +54.0% | +12.0% | +45.0% | -48.2% | -46.3% | -57.4% | -63.6% | |
| Quick Ratio | 5.82 | 5.82 | 6.40 | 6.55 | 5.96 | 5.01 | 4.92 | 4.94 | 4.83 | 2.68 | 3.17 | 4.38 | 3.33 |
| — | +16.3% | +30.1% | +32.5% | +23.4% | +86.9% | +55.6% | +12.8% | +45.4% | -50.9% | -47.5% | -58.0% | -64.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -140.33 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCatalyst Pharmaceuticals, Inc.'s current P/E is 13.7x. The average P/E over the last 4 quarters is 13.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Catalyst Pharmaceuticals, Inc.'s current operating margin is 43.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Catalyst Pharmaceuticals, Inc.'s business trajectory between earnings reports.